WeRide Inc. — Share Issue/Capital Change 2001

Mar 9, 2001

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FAR EAST PHARMACEUTICAL TECHNOLOGY COMPANY LIMITED

（ 遠 東 生 物 制 藥 科 技 有 限 公 司 ）

(Incorporated in the Cayman Islands with limited liability)

Exercise of Over-Allotment Option

On 8th March, 2001, Guotai Junan Securities (Hong Kong) Limited fully exercised the Over-allotment Option in respect of 5,000,000 additional existing Shares (the "Over-allotment Shares") at an issue price HK$1.00 per Share.

Unless otherwise defined, terms used herein shall have the same meanings as defined in the announcement ("Announcement") of Far East Pharmaceutical Technology Company Limited (the "Company") dated 7th March, 2001.

The Company announces that the Over-allotment Option in respect of the Over-allotment Shares referred to in the Announcement was fully exercised by Guotai Junan Securities (Hong Kong) Limited on 8th March, 2001, solely to cover over-allocations in the Placing. The Over-allotment Shares were placed at a price of HK$1.00 per Share. The placees are third parties independent of, and not acting in concert with, any of the directors, chief executives or substantial shareholders of the Company, or its subsidiaries or any of their respective associates (as defined in the Listing Rules).

As a result of the exercise of the Over-allotment Option by Guotai Junan Securities (Hong Kong) Limited, Great Wall Investment Group Limited (the "Vendor"), the substantial shareholder of the Company, has placed a total of 20,000,000 existing Shares to investors under the Placing which represent about 6.25 per cent. of the existing issued share capital of the Company and represent about approximately 5.88 per cent. of the enlarged issued share capital of the Company immediately after completion of the Placing and the Subscription. Upon completion of the Placing (including the Over-allotment Shares), the interest of the Vendor, in the issued share capital of the Company will be reduced from 75.00 per cent. to approximately 68.75 per cent. Such interest will then be increased to approximately 70.59 per cent. after completion of the Placing and the Subscription.

By order of the Board

Far East Pharmaceutical Technology Company Limited

Cai Chong Zhen

Executive Director

Hong Kong, 8th March, 2001

Please also refer to the published version of this announcement in the i-Mail.